Mylan (MYL) Unit Launches First Generic Teveten Tabs

Mylan Inc. (Nasdaq: MYL) subsidiary, Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base). This product is the generic version of Abbott Laboratories' (NYSE: ABT) Teveten Tablets, which are used to treat hypertension.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
• Albemarle names Max Hood as chief accounting officer
• RenX Enterprises agrees to sell Georgia property for $2.6M